Literature DB >> 16778591

A simple and sensitive method for detecting major mutations within the tyrosine kinase domain of the epidermal growth factor receptor gene in non-small-cell lung carcinoma.

Hiroaki Ohnishi1, Kouki Ohtsuka, Akiko Ooide, Satsuki Matsushima, Tomoyuki Goya, Takashi Watanabe.   

Abstract

The detection of mutations in the epidermal growth factor receptor (EGFR) gene impacts therapeutic decision-making for non-small-cell lung carcinoma (NSCLC). Although direct sequencing has been most frequently used to detect EGFR mutations, this method displays several disadvantages. We set up simple mutation-specific polymerase chain reaction (PCR) for common delE746-A750 and L858R mutations of EGFR using primers specific to these mutations. Both mutation-specific PCR and direct sequencing methods were used to investigate 62 samples of NSCLC, and the results were compared. To evaluate the sensitivity of mutation-specific PCR, DNA mixtures containing various proportions of mutant alleles were analyzed. Mutation-specific PCR revealed delE746-A750 in 8 samples and L858R in 14 samples. All samples with either delE746-A750 or L858R mutation revealed by direct sequencing also displayed positive results for mutation-specific PCR. Conversely, mutations in 3 samples revealed by L858R-specific PCR were barely detectable by direct sequencing. In DNA mixture analysis, DNA mixtures containing 2.5% of delE746-A750 allele or 0.25% of L858R allele yielded positive results with mutation-specific PCR. Our mutation-specific PCR showed satisfactory sensitivity and reliability for detecting major EGFR mutations in clinical NSCLC samples. Given the practical availability, this method could be widely applicable to the treatment of lung cancers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16778591     DOI: 10.1097/00019606-200606000-00007

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  10 in total

Review 1.  Targeted deep resequencing of the human cancer genome using next-generation technologies.

Authors:  Samuel Myllykangas; Hanlee P Ji
Journal:  Biotechnol Genet Eng Rev       Date:  2010

2.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  J Thorac Oncol       Date:  2013-07       Impact factor: 15.609

3.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  Arch Pathol Lab Med       Date:  2013-04-03       Impact factor: 5.534

4.  Molecular alterations of EGFR in small intestinal adenocarcinoma.

Authors:  Yan Wang; Cong-Qing Jiang; Jing Guan; Gui-Fang Yang; Jun-Qiu Yue; Hong-Lei Chen; Jing-Ling Xue; Zhi-Gao Xu; Qun Qian; Li-Fang Fan
Journal:  Int J Colorectal Dis       Date:  2013-05-04       Impact factor: 2.571

5.  Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer.

Authors:  Sara Simonetti; Miguel Angel Molina; Cristina Queralt; Itziar de Aguirre; Clara Mayo; Jordi Bertran-Alamillo; José Javier Sanchez; Jose Luis Gonzalez-Larriba; Ulpiano Jimenez; Dolores Isla; Teresa Moran; Santiago Viteri; Carlos Camps; Rosario Garcia-Campelo; Bartomeu Massuti; Susana Benlloch; Santiago Ramon y Cajal; Miquel Taron; Rafael Rosell
Journal:  J Transl Med       Date:  2010-12-18       Impact factor: 5.531

6.  Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.

Authors:  Tomokazu Kishiki; Hiroaki Ohnishi; Tadahiko Masaki; Kouki Ohtsuka; Yasuo Ohkura; Jyunji Furuse; Takashi Watanabe; Masanori Sugiyama
Journal:  Cancer Chemother Pharmacol       Date:  2014-02-06       Impact factor: 3.333

7.  Quantum dots immunofluorescence histochemical detection of EGFR gene mutations in the non-small cell lung cancers using mutation-specific antibodies.

Authors:  Yan-Gang Qu; Qian Zhang; Qi Pan; Xian-Da Zhao; Yan-Hua Huang; Fu-Chun Chen; Hong-Lei Chen
Journal:  Int J Nanomedicine       Date:  2014-12-09

8.  KRAS Mutation as a Potential Prognostic Biomarker of Biliary Tract Cancers.

Authors:  Masaaki Yokoyama; Hiroaki Ohnishi; Kouki Ohtsuka; Satsuki Matsushima; Yasuo Ohkura; Junji Furuse; Takashi Watanabe; Toshiyuki Mori; Masanori Sugiyama
Journal:  Jpn Clin Med       Date:  2016-12-13

9.  Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing.

Authors:  Luisella Righi; Alessandra Cuccurullo; Simona Vatrano; Susanna Cappia; Daniela Giachino; Paolo De Giuli; Mara Ardine; Silvia Novello; Marco Volante; Giorgio V Scagliotti; Mauro Papotti
Journal:  BMC Cancer       Date:  2013-03-13       Impact factor: 4.430

Review 10.  EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples.

Authors:  Gillian Ellison; Guanshan Zhu; Alexandros Moulis; Simon Dearden; Georgina Speake; Rose McCormack
Journal:  J Clin Pathol       Date:  2012-11-21       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.